{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.2174","upperLimit":"0.4666","value":"0.3401"},{"groupId":"OG001","lowerLimit":"0.1267","upperLimit":"0.7345","value":"0.4500"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"description":"Estimated 4-year EFS where EFS is calculated as the time from study enrollment to disease progression, disease relapse, occurrence of a second malignant neoplasm, death from any cause or last follow-up whichever occurs first. Kaplan-Meier method is used for estimation. Patients without an event are censored at last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Infants (\\<36 months of age) with tumor histology and immunohistochemical analysis diagnostic of AT/RT.","id":"OG000","title":"Stratum I"},{"description":"Older children (greater than 36 months of age) with tumor histology and immunohistochemical analysis diagnostic of AT/RT.","id":"OG001","title":"Stratum III"}],"paramType":"NUMBER","populationDescription":"One patient was ineligible in stratum I and one patient was ineligible in stratum III. There were no patients enrolled in Stratum 2 or 4.","reportingStatus":"POSTED","timeFrame":"Up to 4 years after study enrollment","title":"Event-free Survival","type":"PRIMARY","unitOfMeasure":"Estimated probability"}